A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy - ARDA+

argenx BV0 个研究点目标入组 48 人开始时间: 2022年9月19日最近更新: 2024年4月15日

研究概览

暂无简介。

•Participants are eligible to be included in the trial only if all of the following criteria apply:
•1. Capable of providing signed informed consent, and complying with protocol requirements. Participants must be able to read and write.
•2. Must have completed the double-blinded treatment period of the ARGX-117-2002 trial and considered to be eligible for treatment with ARGX-117
•3. Agrees to use contraceptive measures consistent with local regulations and the following:
•a. Male participants: must use an acceptable contraceptive method that should be maintained at minimum until 15 months after last dose of Investigational Medicinal Product (IMP).
•b. Female participants (women) of childbearing potential must have a negative urine pregnancy test at baseline before IMP can be administered.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 36
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 12

•Participants will be excluded from the trial if any of the following criteria apply:
•1. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection
•2. Clinical evidence of other significant serious diseases, have had a recent major surgery, or who have any other condition, in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk.
•3. Currently participating in another interventional clinical study
•4. Pregnant or lactating or intend to become pregnant during the trial or within 15 months after last dose of the IMP.

发起方